在COVID-19大流行期间,癌症患者的血栓塞栓事件:病例控制研究研究
Vivian Cristina Gama Souza Lima1,2, Paulo Jorge Pereira Alves3, Patrícia Dos Santos Claro Fuly1
1Universidade Federal Fluminense, Escola de Enfermagem Aurora de Afonso Costa, Niterói, RJ, Brazil.
Revista latino-americana de enfermagem
|August 21, 2024
概括
冠状病毒疾病 (COVID-19) 在第一年大流行期间没有增加癌症患者血栓栓塞事件的风险. 与癌症及其治疗相关的因素与这些事件有关.
科学领域:
- 在瘤学瘤学.
- 传染性疾病 传染性疾病
- 血液学 血液学 血液学
背景情况:
- 血栓栓塞事件 (TE) 是癌症患者的一个重大问题.
- 早期的COVID-19大流行引发了关于其对这种脆弱人群中TE的影响的问题.
研究的目的:
- 分析冠状病毒疾病 (COVID-19) 感染和癌症患者的血栓栓塞事件在流行病的第一年之间的关联.
主要方法:
- 通过使用成人癌症患者的医疗记录进行了一项病例控制研究.
- 病例发生了血栓塞栓事件;对照组没有. 统计分析包括皮尔森的千平方和物流回归.
主要成果:
- 这项研究包括388例病例和440例对照. 深静脉血栓是病例中最常见的事件.
- 抗瘤化疗是常见的. 在11.59%的参与者中发现了COVID-19.
- 化疗增加了TEs的几率65%,TEs与更高的死亡率有关.
结论:
- 没有发现冠状病毒疾病 (COVID-19) 感染会增加癌症患者血栓栓塞事件的可能性.
- 这种人群中TEs的风险因素主要与癌症本身及其治疗有关,而不是COVID-19.
相关概念视频
Cancer Therapies
7.6K
Cancer therapies are various modes of treatment, such as surgery, radiation therapy, and chemotherapy that are administered to cancer patients.
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
7.6K
Disorders of Hemostasis
758
Hemostasis, the process that stops bleeding after a blood vessel injury, is crucial for maintaining the integrity of the circulatory system. However, disorders of hemostasis can disrupt this delicate balance, leading to either excessive clotting or bleeding. These disorders can be broadly classified into thromboembolic disorders and bleeding disorders.
Thromboembolic Disorders
Two factors primarily cause thromboembolic conditions.
Thromboembolic Disorders
Two factors primarily cause thromboembolic conditions.
758
Cancer Survival Analysis
334
Cancer survival analysis focuses on quantifying and interpreting the time from a key starting point, such as diagnosis or the initiation of treatment, to a specific endpoint, such as remission or death. This analysis provides critical insights into treatment effectiveness and factors that influence patient outcomes, helping to shape clinical decisions and guide prognostic evaluations. A cornerstone of oncology research, survival analysis tackles the challenges of skewed, non-normally...
334
Rous Sarcoma Virus (RSV) and Cancer
5.0K
Rous Sarcoma virus or RSV was discovered by F. Peyton Rous in the year 1911 as a filterable transmissible agent that could cause tumors in chickens. He won a Nobel Prize for this discovery in 1966. His experiments clearly demonstrated that some cancers could be caused by infectious agents and led to the discovery of many more cancer-causing viruses in animals as well as humans.
RSV is a retrovirus that contains two copies of a plus-strand RNA genome. Its genome consists of four main open...
RSV is a retrovirus that contains two copies of a plus-strand RNA genome. Its genome consists of four main open...
5.0K
Anticoagulant Drugs: Low-Molecular-Weight Heparins
654
Hemostasis is a crucial process that prevents excessive blood loss from damaged blood vessels. It involves various mechanisms such as vasoconstriction, platelet adhesion and activation, and fibrin formation. The importance of each mechanism depends on the type of vessel injury. In contrast, thrombosis is the abnormal formation of a blood clot within the blood vessels, leading to potential complications if the clot obstructs blood flow. Thrombosis can be caused by increased coagulability of the...
654


